Introduction
============

Nonsteroidal anti-inflammatory drugs (NSAIDs) are an integral part of multimodal postoperative analgesic regimens, which rely on combinations of medications from different analgesic classes to provide pain relief while limiting adverse effects associated with individual classes.[@b1-cpaa-8-203],[@b2-cpaa-8-203] There are, however, relatively few available options in the United States for fast-acting injectable NSAIDs that are appropriate for management of postoperative pain. Furthermore, NSAIDs can present risks of serious complications and are thus either not used in certain populations or require dose adjustments that can limit their efficacy.[@b3-cpaa-8-203]

Surgeries in high-risk populations present a challenge for appropriate pain management. One such high-risk population is the elderly, who represent an increasing proportion of the general population, are increasingly likely to undergo major surgery,[@b4-cpaa-8-203] and are more likely to have comorbidities and suffer complications of surgery.[@b5-cpaa-8-203] In addition, age-related changes in drug metabolism may cause changes in drug half-life or sensitivity, and susceptibility to the side effects of opioid analgesics, such as delirium, sedation, and obstructive apnea, may be increased in the elderly.[@b4-cpaa-8-203] Overweight patients also represent a substantial segment of the population, with the proportion of US adults who are obese estimated to exceed 35%.[@b6-cpaa-8-203] With respect to postoperative pain management, obese patients are particularly susceptible to changes in drug disposition, which may require increases or decreases in dosing paradigms to maximize efficacy and minimize safety concerns. Exacerbation of postsurgical respiratory complications related to obstructive sleep apnea that are common in obese populations can arise with opioid use,[@b7-cpaa-8-203] and guidelines for postoperative pain management in obese patients emphasize the use of local anesthetics and NSAIDs.[@b8-cpaa-8-203],[@b9-cpaa-8-203] Taken together, the requirements and challenges related to pain management in both elderly and obese populations highlight the need for improved understanding of the pharmacokinetic (PK) factors that may impact patient safety and response to analgesic therapy.

The NSAID diclofenac inhibits both cyclooxygenase (COX)-1 and COX-2[@b10-cpaa-8-203] and has well-established efficacy in treating acute postoperative pain.[@b11-cpaa-8-203]--[@b13-cpaa-8-203] Hydroxypropyl-β-cyclodextrin (HPβCD)-diclofenac (Dyloject™, Hospira, a Pfizer company, Lake Forest, IL, USA) is an injectable formulation of diclofenac solubilized with HPβCD that is approved for use in the United States. A previous intravenous (IV) diclofenac formulation available only outside of the United States employs propylene glycol and benzyl alcohol for solubilization and requires prolonged IV infusion times to avoid solvent-associated vascular irritation.[@b14-cpaa-8-203],[@b15-cpaa-8-203] This formulation must also be diluted and buffered with sodium bicarbonate and administered immediately following preparation.[@b15-cpaa-8-203] HPβCD-diclofenac, a stable, ready-to-use solution, minimizes the risks associated with the preparation and administration of parenteral drugs.[@b16-cpaa-8-203],[@b17-cpaa-8-203] In clinical trials, HPβCD-diclofenac has demonstrated safety and efficacy in treating pain following dental, abdominal/pelvic, and orthopedic surgery,[@b18-cpaa-8-203]--[@b21-cpaa-8-203] as well as less platelet inhibition than the NSAID ketorolac and acetylsalicylic acid in healthy subjects.[@b22-cpaa-8-203] In addition, a previous study has reported the PK of diclofenac after single and multiple doses of HPβCD-diclofenac in healthy adult (≥18 years old) volunteers.[@b23-cpaa-8-203] The objective of this study was to evaluate the PK of HPβCD-diclofenac in adult subjects based on age and weight (including adjustments for body mass index \[BMI\]).

Methods
=======

Study population
----------------

A total of 340 individuals were screened for inclusion in the study ([Figure 1](#f1-cpaa-8-203){ref-type="fig"}). Overall, 151 individuals met the study screening criteria. Seventeen of these individuals were not enrolled given that the groups to which they were to be assigned had already been filled. In addition, 31 eligible subjects withdrew consent after screening. There were 88 total participants in the study, which was conducted at two US sites, PAREXEL Clinical Pharmacology Research in Baltimore, MD, and Comprehensive Phase One in Miramar, FL. The clinical study protocol, written informed consent forms, and any amendments requiring approval were reviewed and approved by The Chesapeake Research Review, Inc. institutional review board for both study sites. All study participants provided written informed consent to be included in the study. Subjects were assigned to one of two study cohorts, which were based on age and weight/BMI, respectively. Subjects enrolled into the age-based cohort were required to be ≥55 years of age and have body weight 45--95 kg and BMI 19--30 kg/m^2^. Subjects enrolled into the weight-based cohort were required to be 18--55 years of age and have body weight 40--159 kg and BMI ≥15 kg/m^2^. All volunteers were required to be nonsmokers, healthy enough for study participation, and able to communicate with study personnel. Premenopausal female volunteers were required to have a negative pregnancy test, be nonlactating, and practicing an approved form of contraception. Subjects were excluded if they had any significant medical history or clinically relevant laboratory test results, were serologically positive for the human immunodeficiency virus, hepatitis B virus, or hepatitis C virus, had hypersensitivity to NSAIDs or diclofenac, or were substance abusers. Restrictions were placed on certain disease states, such as current intestinal disorders or infections, peptic ulcers, gastrointestinal bleeding, or cerebral hemorrhage, as well as specific previous surgeries, including bariatric surgery and bowel resection. Only specified concomitant medications, such as appetite suppressants or herbal medications for subjects in the weight-based cohort, resulted in exclusion from the study. Volunteers with a history of cardiovascular events, diabetes, high blood pressure, and/or hypercholesterolemia were allowed to enroll in the study, provided that the investigator judged that study participation would not put subject health at risk.

Study design
------------

Subjects in the age-based cohort were stratified into three groups: age 55--64 years, 65--74 years, and ≥75 years. Subjects in the weight-based cohort were stratified into five groups: underweight (weight not defined, BMI 15--18.9 kg/m^2^), small (weight ≥45 kg and \<60 kg, BMI 19--24.9 kg/m^2^), large (weight 60--100 kg, BMI ≥19 kg/m^2^ and \<30 kg/m^2^), obese (weight not defined, BMI 30--40 kg/m^2^), and extremely obese (weight not defined, BMI \>40 kg/m^2^; [Figure 1](#f1-cpaa-8-203){ref-type="fig"}). In addition to the PK analyses carried out in the defined age- and weight-based patient cohorts, data from all subjects were combined and regression analyses were performed to examine the effect of age, weight, and BMI on the independent PK parameters total plasma clearance (CL) and volume of distribution (*V*~z~) and the dependent PK parameter elimination half-life (*t*~1/2~) in the pooled subject population.

Subjects were fasted overnight before a single dose of IV HPβCD-diclofenac was administered the following morning. Subjects received a standard light breakfast approximately 2.5 hours after dosing, followed by lunch and dinner approximately 4 and 10 hours after dosing, respectively. On the basis of the results of a previous PK and bioavailability study and postoperative efficacy studies,[@b18-cpaa-8-203],[@b20-cpaa-8-203],[@b23-cpaa-8-203] subjects in the weight-based cohort received an IV bolus of HPβCD-diclofenac 37.5 mg. Subjects in the age-based cohort received an IV bolus of HPβCD-diclofenac 18.75 mg. A conservative dosing methodology was chosen given that this was the first clinical study in which subjects ≥65 years of age were administered HPβCD-diclofenac, and in line with typical recommendations for reduced NSAID dosage in elderly patients.[@b4-cpaa-8-203]

Blood samples for PK analysis were obtained via an indwelling IV cannula or by direct venipuncture at the following time points: Time 0 (predosing), 5, 10, 20, 30, and 45 minutes and 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, and 18 hours postdosing. For samples from an indwelling catheter, the first 2 mL of blood were drawn into a separate syringe and discarded to clear saline diluent in tubing dead space, and the last 3 mL were collected for analysis. Blood was collected for analysis in prelabeled 3 mL Vacutainer® tubes (Becton Dickinson, Franklin Lakes, NJ, USA) containing di-potassium ethylenediaminetetraacetic acid (K~2~-EDTA) as an anticoagulant.

PK and statistical analysis
---------------------------

Plasma diclofenac concentrations were measured using a validated liquid chromatography-tandem mass spectrometry method (range: 5--2,000 ng/mL; lower limit of quantitation (LOQ) =5 ng/mL) performed by CEDRA Clinical Research, LLC (Austin, TX, USA). One subject in the weight-based cohort and six subjects in the age-based cohort had plasma diclofenac concentrations that were considered aberrant. Two subjects had concentrations at 5 minutes postdrug injection that were 8- and 30-fold higher, respectively, than the mean concentration at that time point excluding those subjects. The aberrant concentrations in the other five subjects essentially occurred during the elimination phase, ranging from 10.5- to 934-fold concentration increases from the preceding samples in these subjects. PK analyses were performed both including and excluding these subjects. The overall conclusions of the study and relationship between diclofenac CL, *t*~1/2~, *V*~z~, and age or weight did not change as a result of including subjects with apparent aberrant plasma concentrations. The PK results presented here have excluded these subjects. The safety population included all subjects who received the study drug. Safety was assessed during the study by monitoring adverse events (AEs), concomitant medications, vital signs, laboratory results, and electrocardiogram and physical examination results.

PK parameters were calculated using noncompartmental analysis. Only plasma concentrations equal to or greater than the LOQ were used in the analysis. Actual sampling times were used in all PK analyses. Per protocol times were used to calculate mean plasma concentrations for graphical displays. The maximum plasma concentration (*C*~max~) and time to *C*~max~ (*T*~max~) were taken directly from the data. The elimination rate constant, λ~z~, was calculated as the negative of the slope of the terminal log-linear segment of the plasma concentration--time curve. The range of data used for each subject and treatment was determined by visual inspection of a semilogarithmic plot of concentration vs time. *t*~1/2~ was calculated according to the equation *t*~1/2~=0.693/λ~z~. The area under the curve (AUC) from zero to the final sample with a concentration ≥LOQ (AUC~(0--t)~) was calculated using the linear trapezoidal method and extrapolated to infinity using AUC∞ = AUC~(0--t)~ + CTF/λ~z~, where CTF is the final concentration ≥LOQ. CL was calculated as dose/AUC, and *V*~z~ was calculated as dose/(λ~z~ × AUC). All PK calculations and plasma concentration vs time graphs were prepared using SAS® for Windows® Version 9.1.3 (SAS Institute Inc., Cary, NC, USA). Data for continuous PK parameters in the cohort analyses are presented as mean ± standard deviation. For linear regression analysis of PK parameters in relation to age, weight, and BMI, statistical significance was assessed via one-way analysis of variance, with *P*\<0.05 defined as statistically significant.

Results
=======

PK: cohort analyses
-------------------

All 88 subjects enrolled in the age- and weight-based cohorts completed the study. The demographic characteristics of the study population are summarized in [Table 1](#t1-cpaa-8-203){ref-type="table"}. In total, there were 36 male subjects and 52 female subjects enrolled. PK analysis in the subjects in the age-based cohort showed no effect of age (in subjects aged 55--82 years) on the exposure of IV HPβCD-diclofenac. Mean plasma diclofenac concentration--time curves were similar for the three age groups examined ([Figure 2A](#f2-cpaa-8-203){ref-type="fig"}), and overall, mean diclofenac PK parameter values were similar between groups ([Table 2](#t2-cpaa-8-203){ref-type="table"}). Data from patients ≥75 years old suggest possible increases in *t*~1/2~ and *V*~z~, as well as a possible decrease in λ~z~, compared to the other two age groups in the cohort; however, the low number of subjects in this group (n=3) limits the conclusions that can be drawn. Similar to results from the age-based cohort, mean plasma diclofenac concentration--time curves were essentially the same for the five groups in the weight-based cohort ([Figure 2B](#f2-cpaa-8-203){ref-type="fig"}). Mean diclofenac PK parameter values were also similar across groups in the weight-based cohort, although there was a general trend toward increased CL and *V*~z~ in higher weight groups ([Table 3](#t3-cpaa-8-203){ref-type="table"}).

PK: pooled population
---------------------

Because age and weight are continuous variables, data from the age- and weight-based cohorts were combined and regression analyses were performed on the pooled population to further investigate the relationship between age, weight, and diclofenac PK. Examination of the relationships between age and CL, *V*~z~, and *t*~1/2~ for the pooled population indicated that there was a significant inverse relationship between age and *V*~z~ (*P*=0.018), as well as between age and t½ (*P*=0.048; [Figure 3](#f3-cpaa-8-203){ref-type="fig"}). Specifically, with increasing age, there was a significant decrease in *V*~z~, which resulted in a significant decrease in *t*~1/2~. Conversely, regression analysis of the pooled population revealed that diclofenac CL was not significantly affected by age (*P*=0.18).

Examination of the relationships between weight and CL, *V*~z~, and *t*~1/2~ in the pooled population indicated that there were significant relationships between increasing weight and increasing CL, as well as weight and increasing *V*~z~ (both *P*\<0.0001; [Figure 4](#f4-cpaa-8-203){ref-type="fig"}). There was essentially no relationship between weight and *t*~1/2~ (*P*=0.49), due to proportional increases in both CL and *V*~z~. Relationships with BMI were consistent with those for weight, a major component of BMI.

Safety
------

There were no deaths, no serious AEs, and no AEs that led to discontinuation from the study in either the age- or weight-based cohort. Three subjects (8.8%) in the age-based cohort reported a total of 13 treatment-emergent AEs ([Table 4](#t4-cpaa-8-203){ref-type="table"}). All events were considered to be mild and transient, and all but two (one incidence each of pruritus and hypertension) resolved without medical intervention. In the weight-based cohort ([Table 5](#t5-cpaa-8-203){ref-type="table"}), n=9 subjects (16.7%) reported 14 treatment-emergent AEs. All AEs in the weight-based cohort were also considered to be mild and transient, and all were resolved without medical intervention. In the age-based cohort, 54.5% of AEs were considered by the investigator to be unrelated to study drug, while 57.1% of those in the weight-based cohort were considered unrelated.

Discussion
==========

This study extends previous findings by demonstrating the PK of diclofenac based on age and weight following injection of a single dose of HPβCD-diclofenac. Analysis of diclofenac PK in all subjects demonstrated that increasing age had no effect on the total exposure of IV HPβCD-diclofenac, but did show a significant inverse relationship between age and *V*~z~, as well as age and *t*~1/2~. This suggests a decreased risk of accumulation in elderly subjects. In addition, analysis of the pooled cohort demonstrated a significant increase in diclofenac CL, and thus decreased exposure, with increasing weight. There were no deaths, no serious AEs, and no AEs that led to discontinuation from the study in any subject.

NSAID dosages are typically reduced in the elderly because this patient group can be particularly susceptible to adverse effects associated with NSAID use, such as bleeding, renal, and cardiovascular complications.[@b4-cpaa-8-203] Dosage reductions are required for IV ketorolac, for example, given that it may be cleared more slowly in the elderly and in light of the elevated sensitivity of elderly patients to dose-related adverse effects of NSAIDs, such as gastrointestinal bleeding.[@b24-cpaa-8-203] Importantly, HPβCD-diclofenac, with its balanced COX inhibition profile, may potentially pose less risk of postoperative bleeding than NSAIDs that preferentially inhibit COX-1. In a study of platelet function in human volunteers, HPβCD-diclofenac affected clotting ability to a lesser extent than ketorolac and acetylsalicylic acid.[@b22-cpaa-8-203] Also noteworthy are findings from a pivotal Phase III safety study of multiple-dose HPβCD-diclofenac in a large postoperative patient population, which demonstrated that the incidence of bleeding-related AEs was not increased in patients ≥65 years old vs patients \<65 years old.[@b21-cpaa-8-203]

Consistent with existing guidelines regarding NSAID dosage in elderly patients, elderly subjects in this study were given HPβCD-diclofenac 18.75 mg, half of the standard 37.5 mg dose. The study results demonstrate that subject age did not affect the overall exposure of diclofenac. Age-related changes in body water and body fat, however, affect the volume of distribution (*V*~z~) of drugs in older patients.[@b4-cpaa-8-203] In this study, pooled analysis of PK data from all subjects revealed a significant decrease in diclofenac *V*~z~, which resulted in a significant decrease in *t*~1/2~, with increased age. This suggests that there would be a decreased risk of accumulation of diclofenac in elderly subjects and that HPβCD-diclofenac dose reduction in elderly patients may not be warranted. Notably, a recent study also demonstrated no accumulation of diclofenac in healthy adult volunteers following multiple HPβCD-diclofenac doses.[@b23-cpaa-8-203] Analysis of this study's age-based cohort also suggests possible increases in *t*~1/2~ and *V*~z~ and a possible decrease in λ~z~ in subjects ≥75 years old; however, the number of subjects in this age group in this study was limited (n=3). Thus, further PK investigation in this age group would likely be beneficial.

The results of this study also indicate an association between patient weight and diclofenac PK, as evidenced by a decrease in exposure with increasing body weight. In general, the effect of patient weight on *V*~z~ varies with the physio-chemical attributes of a given drug, such as molecular size, lipid solubility, and ability to cross biological membranes. For example, the *V*~z~ for lipophilic drugs may be increased in higher weight patients due to an increased proportion of adipose tissue.[@b25-cpaa-8-203] CL may also be altered in obese patients due to the presence of fatty liver disease that may affect drug metabolism.[@b25-cpaa-8-203] In this study, we observed proportional increases in both *V*~z~ and CL with increased body weight, such that the *t*~1/2~ of diclofenac was not altered. Dosing adjustments for high-weight patients have been recommended for ibuprofen to achieve analgesia while maintaining the same dosing interval.[@b9-cpaa-8-203] While the PK of diclofenac following HPβCD-diclofenac administration appear to be dependent on body weight, the effect of weight on the clinical efficacy and safety of HPβCD-diclofenac has not been fully studied, and thus dose adjustments for weight based on these PK findings alone are not recommended.

Conclusion
==========

In summary, a uniform 37.5 mg dose of HPβCD-diclofenac for adult patients offers the benefit of simplifying treatment, reducing dosing errors, and saving time spent on dose calculations. The results of this study suggest that the CL of HPβCD-diclofenac is not altered in elderly subjects when administered at the usual dose and schedule but may be impacted by body weight.
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![Distribution of subjects assigned to age- and weight-based cohorts.\
**Notes:** A total of n=88 subjects were assigned to either the age- or weight-based cohort. All subjects completed the study. ^a^Weight groups defined as follows: underweight: BMI 15--18.9 kg/m^2^; small: BMI 19--24.9 kg/m^2^, weight ≥45 kg and \<60 kg; large: BMI ≥19 kg/m^2^ and \<30 kg/m^2^, weight 60--100 kg; obese: BMI 30--40 kg/m^2^; extremely obese: BMI \>40 kg/m^2^.\
**Abbreviation:** BMI, body mass index.](cpaa-8-203Fig1){#f1-cpaa-8-203}

![The effect of age and weight on diclofenac plasma concentration.\
**Notes: (A)** Mean plasma diclofenac concentration over time following IV administration of HPβCD-diclofenac 18.75 mg to subjects in the age-based cohort (age range: 55--82 years). **(B)** Mean plasma diclofenac concentration over time following IV administration of HPβCD-diclofenac 37.5 mg to patients in the weight-based cohort.\
**Abbreviations:** BMI, body mass index; HPβCD, hydroxypropyl-β-cyclodextrin; IV, intravenous.](cpaa-8-203Fig2){#f2-cpaa-8-203}

![Association between age and diclofenac PK parameters.\
**Notes:** Relationship between volume of distribution (*V*~z~); (**A**), terminal elimination half-life (*t*~1/2~); (**B**), and CL (**C**) and age following IV administration of HPβCD-diclofenac 18.75 or 37.5 mg. Subjects from the age- and weight-based cohorts were pooled. There was a statistically significant inverse relationship between age and *V*~z~ (*P*=0.018) and *t*~1/2~ (*P*=0.048), and a nonstatistically significant relationship between age and CL (*P*=0.18). Subjects with aberrant plasma diclofenac measurements were excluded.\
**Abbreviations:** HPβCD, hydroxypropyl-β-cyclodextrin; PK, pharmacokinetics; CL, clearance.](cpaa-8-203Fig3){#f3-cpaa-8-203}

![Association between weight and diclofenac PK parameters.\
**Notes:** Relationship between volume of distribution (*V*~z~); (**A**), terminal elimination half-life (*t*~1/2~); (**B**), and CL (**C**) and weight following IV administration of HPβCD-diclofenac 18.75 or 37.5 mg. Subjects from the age- and weight-based cohorts were pooled. There was a statistically significant relationship between weight and *V*~z~ and weight and CL (both *P*\<0.0001), and a nonstatistically significant relationship between weight and *t*~1/2~ (*P*=0.49). Subjects with aberrant plasma diclofenac measurements were excluded.\
**Abbreviations:** HPβCD, hydroxypropyl-β-cyclodextrin; PK, pharmacokinetics; CL, clearance.](cpaa-8-203Fig4){#f4-cpaa-8-203}

###### 

Demographic characteristics of study subjects

  Cohort (n)          HPβCD-diclofenac dose, mg   Age range, years      Group (n)[a](#tfn1-cpaa-8-203){ref-type="table-fn"}   Mean age, years (SD)   Mean weight, kg (SD)   Mean BMI, kg/m^2^ (SD)   Sex, male/female, n   Race, Black or African American/White, n
  ------------------- --------------------------- --------------------- ----------------------------------------------------- ---------------------- ---------------------- ------------------------ --------------------- ------------------------------------------
  Age based (34)      18.75                       55--82                55--64 years (15)                                     57.6 (2.5)             68.65 (9.77)           25.95 (2.80)             13/21                 3/31
                                                  65--74 years (14)     68.4 (2.8)                                            67.01 (8.93)           26.32 (2.42)                                                          
                                                  Age ≥75 years (5)     78.0 (3.1)                                            72.20 (6.42)           27.78 (1.77)                                                          
  Weight based (54)   37.5                        18--54                Underweight (5)                                       28.0 (8.0)             52.00 (7.16)           18.00 (0.63)             23/31                 33/21
                                                  Small (11)            32.5 (11.1)                                           54.27 (3.79)           21.19 (1.77)                                                          
                                                  Large (16)            34.5 (12.5)                                           81.53 (10.29)          27.08 (2.01)                                                          
                                                  Obese (13)            36.9 (9.2)                                            99.14 (11.13)          34.21 (2.37)                                                          
                                                  Extremely obese (9)   38.7 (8.4)                                            126.82 (20.64)         43.66 (2.47)                                                          

**Notes:**

Weight groups defined as follows: underweight: BMI 15--18.9 kg/m^2^; small: BMI 19--24.9 kg/m^2^, weight ≥45 kg and \<60 kg; large: BMI ≥19 kg/m^2^ and \<30 kg/m^2^, weight 60--100 kg; obese: BMI 30--40 kg/m^2^; extremely obese: BMI \>40 kg/m^2^.

**Abbreviations:** HPβCD, hydroxypropyl-β-cyclodextrin; BMI, body mass index; SD, standard deviation.

###### 

PK parameters of HPβCD-diclofenac in the age-based cohort (n=28 subjects; excludes subjects with aberrant plasma diclofenac measurements)

  Parameter[a](#tfn3-cpaa-8-203){ref-type="table-fn"}   Age group                                 
  ----------------------------------------------------- -------------------- -------------------- -------------------
  *C*~max~ (ng/mL)                                      3,439 ±855 (12)      3,465 ±738 (13)      3,257±750 (3)
  *T*~max~ (h)                                          0.083 (12)           0.083 (13)           0.083 (3)
  AUC~(0--*t*)~(h × ng/mL)                              1,087±288 (12)       1,143 ±261 (13)      1,200±95.9 (3)
  AUC∞ (h × ng/mL)                                      1,126±291 (11)       1,178 ±263 (12)      1,220±96.8 (3)
  *t*~1/2~ (h)                                          1.39±0.43 (11)       1.42±0.34 (12)       2.14±0.61 (3)
  λ~z~ (h^−1^)                                          0.5437±0.1728 (11)   0.5165±0.1351 (12)   0.3438±0.1035 (3)
  CL (mL/min)                                           274±70.6 (11)        257±52.2 (12)        239±19.8 (3)
  *V*~z~ (L)                                            32.7±13.3 (11)       31.5±9.26 (12)       44.3±13.1 (3)

**Notes:**

Reported as arithmetic mean ± standard deviation (n), except for *T*~max~ for which the median (n) is reported.

**Abbreviations:** *C*~max~, maximum observed plasma concentration; *T*~max~, time at which *C*~max~ is observed; AUC, area under the curve; AUC~(0--*t*)~, AUC up to the last quantifiable concentration; AUC∞, AUC from time zero to infinite time; *t*~1/2~, apparent elimination half-life; λ~z~, terminal elimination rate constant; CL, clearance; *V*~z~, volume of distribution; HPβCD, hydroxypropyl-β-cyclodextrin; PK, pharmacokinetics.

###### 

PK parameters of HPβCD-diclofenac in the weight-based cohort (n=53 subjects; excludes subjects with aberrant plasma diclofenac measurements)

  Parameter[a](#tfn5-cpaa-8-203){ref-type="table-fn"}   Weight group                                                                       
  ----------------------------------------------------- ------------------- -------------------- -------------------- -------------------- -------------------
  *C*~max~ (ng/mL)                                      6,594±2,258 (5)     8,212±1,952 (11)     5,903±1,060 (16)     5,103±0,672 (13)     4,616±1,639 (8)
  *T*~max~ (h)                                          0.083 (5)           0.083 (11)           0.083 (16)           0.083 (13)           0.083 (8)
  AUC~(0--*t*)~(h × ng/mL)                              2,190±609 (5)       2,413±616 (11)       1,916±411 (16)       1,740±265 (13)       1,569±316 (8)
  AUC~∞~ (h × ng/mL)                                    2,103±651 (4)       2,429±616 (11)       1,933±412 (16)       1,757±266 (13)       1,640±302 (7)
  *t*~1/2~ (h)                                          2.03±0.47 (4)       1.67±0.34 (11)       1.79±0.44 (16)       1.56±0.25 (13)       1.81±0.57 (7)
  λ~z~ (h^−1^)                                          0.3593±0.1011 (4)   0.4321±0.0962 (11)   0.4095±0.0997 (16)   0.4568±0.0847 (13)   0.4205±0.1437 (7)
  CL (mL/min)                                           297±92.4 (4)        255±71.4 (11)        314±69.3 (16)        338±53.0 (13)        363±56.0 (7)
  *V*~z~ (L)                                            50.4±14.0 (4)       36.1±10.1 (11)       47.9±13.6 (16)       45.5±9.60 (13)       56.4±19.0 (7)

**Notes:**

Reported as arithmetic mean ± standard deviation (n), except for *T*~max~ for which the median (n) is reported.

**Abbreviations:** *C*~max~, maximum observed plasma concentration; *T*~max~, time at which *C*~max~ is observed; AUC~(0--*t*)~, AUC, area under the curve; AUC up to the last quantifiable concentration; AUC∞, AUC from time zero to infinite time; *t*~1/2~, apparent elimination half-life; λ~z~, terminal elimination rate constant; CL, clearance; *V*~z~, volume of distribution; HPβCD, hydroxypropyl-β-cyclodextrin; PK, pharmacokinetics; BMI, body mass index.

###### 

Treatment-emergent AEs in the age-based cohort (n=34 total subjects)

  System organ class and preferred term                  Age group              
  ------------------------------------------------------ ----------- ---------- ----------
  Total subjects with ≥1 treatment-emergent AE (%)       0           2 (14.3)   1 (20.0)
  GI disorders                                           0           1 (7.1)    0
   Constipation                                          0           1 (7.1)    0
  General disorders and administration site conditions   0           1 (7.1)    0
   Injection site hematoma                               0           1 (7.1)    0
   Injection site hemorrhage                             0           1 (7.1)    0
   Injection site edema                                  0           1 (7.1)    0
   Injection site rash                                   0           1 (7.1)    0
  Injury, poisoning, and procedural complications        0           1 (7.1)    0
   Contusion                                             0           1 (7.1)    0
  Investigations                                         0           1 (7.1)    0
   Blood amylase increased                               0           1 (7.1)    0
   Lipase increased                                      0           1 (7.1)    0
  Nervous system disorders                               0           1 (7.1)    0
   Dizziness                                             0           1 (7.1)    0
  Skin and subcutaneous tissue disorders                 0           1 (7.1)    0
   Erythema                                              0           1 (7.1)    0
   Pruritus                                              0           1 (7.1)    0
  Vascular disorders                                     0           0          1 (20.0)
   Hypertension                                          0           0          1 (20.0)

**Notes:** The data represents treatment-emergent AEs in the age-based cohort; number of subjects with an event (percentage of the total).

**Abbreviations:** AEs, adverse events; GI, gastrointestinal.

###### 

Treatment-emergent AEs in the weight-based cohort (n=54 total subjects)

  System organ class and preferred term                  Weight group                                    
  ------------------------------------------------------ -------------- ---------- ---------- ---------- ---
  Total subjects with ≥1 treatment-emergent AE (%)       0              4 (36.4)   2 (12.5)   3 (23.1)   0
  GI disorders                                           0              0          1 (6.3)    0          0
   Diarrhea                                              0              0          1 (6.3)    0          0
   Flatulence                                            0              0          1 (6.3)    0          0
  General disorders and administration site conditions   0              2 (18.2)   0          1 (7.7)    0
   Fatigue                                               0              1 (9.1)    0          0          0
   Injection site hemorrhage                             0              1 (9.1)    0          0          0
   Injection site induration                             0              0          0          1 (7.7)    0
   Injection site pain                                   0              0          0          1 (7.7)    0
  Injury, poisoning, and procedural complications        0              0          0          1 (7.7)    0
   Contusion                                             0              0          0          1 (7.7)    0
  Musculoskeletal and connectivetissue disorders         0              1 (9.1)    1 (6.3)    0          0
   Arthralgia                                            0              0          1 (6.3)    0          0
   Back pain                                             0              1 (9.1)    0          0          0
  Nervous system disorders                               0              1 (9.1)    0          2 (15.4)   0
   Burning sensation                                     0              1 (9.1)    0          0          0
   Headache                                              0              0          0          2 (15.4)   0
  Psychotic disorders                                    0              1 (9.1)    0          0          0
   Euphoric mood                                         0              1 (9.1)    0          0          0
  Reproductive system and breast disorders               0              1 (9.1)    0          0          0
   Dysmenorrhea                                          0              1 (9.1)    0          0          0

**Notes:** The data represents treatment-emergent AEs in the age-based cohort; number of subjects with an event (percentage of the total).

**Abbreviations:** AEs, adverse events; GI, gastrointestinal; BMI, body mass index.
